Chemotherapy of Leukemia, Hodgkin's Disease and Related Disorders

Article1 September 1954CHEMOTHERAPY OF LEUKEMIA, HODGKIN'S DISEASE AND RELATED DISORDERSM. M. WINTROBE, F.A.C.P., G. E. CARTWRIGHT, PHAEDON FESSAS, ARTHUR HAUT, S. J. ALTMANM. M. WINTROBE, F.A.C.P.Search for more papers by this author, G. E. CARTWRIGHTSearch for more papers by this author, PHAEDON FESSASSearch for more papers by this author, ARTHUR HAUTSearch for more papers by this author, S. J. ALTMANSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-41-3-447 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe object of this report is to discuss the chemotherapy of leukemia, Hodgkin's disease and the related disorders in the light of our own experience since the development of interest in this field 10 years ago.1, 2 A large number of chemotherapeutic agents has been discovered since that time but only a few have earned a solid position in the list of useful drugs.The available chemotherapeutic agents can be best classified and discussed in relation to four groups of disorders, since different ones have been found to be particularly effective in each group. The four groups are as follows:...Bibliography1. JagerWintrobeGinzlerGordon BVMMAMS: Oral ingestion of tris (β-chloroethyl) amine hydrochloride by humans, Report No. 1, Washington, D. C., Medical Research Laboratory, Medical Division, Army Medical Center, September, 1943. Google Scholar2. GoodmanWintrobeDameshekGoodmanGilmanMcLennan LSMMWMJAMT: Nitrogen mustard therapy: Use of methyl-bis (β-chloroethyl) amine hydrochloride and tris (β-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders, J. A. M. A. 132: 126, 1946. CrossrefMedlineGoogle Scholar3. KarnofskyBurchenalArmisteadSouthamBernsteinCraverRhoads DAJHGCCMJLLFCP: Triethylene melamine in the treatment of neoplastic disease. A compound with nitrogen-mustard-like activity suitable for oral and intravenous use, Arch. Int Med. 87: 477, 1951. CrossrefGoogle Scholar4. SykesKarnofskyPhilipsBurchenal MPDAFSJH: Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard-like activity, Cancer 6: 142, 1953. CrossrefGoogle Scholar5. GardikasWilkinson CJF: Trial of β-naphthyl-di-2-chloroethylamine in leukaemia, Hodgkin's disease, and allied disorders, Lancet 1: 137, 1951. CrossrefMedlineGoogle Scholar6. HaddowTimmis AGM: Myleran in chronic myeloid leukaemia. Chemical constitution and biological action, Lancet 1: 207, 1953. CrossrefGoogle Scholar7. PatersonAp ThomasHaddowWatkinson EIAJM: Leukaemia treated with urethane compared with deep x-ray therapy, Lancet 1: 677, 1946. CrossrefMedlineGoogle Scholar8. MoeschlinMeyerLichtman SHA: Ein neues Colchicum-Nebenalkaloid (Demecolcin Ciba) als Cytostaticum myeloischer Leukämien, Schweiz. med. Wchnschr. 83: 990, 1953. MedlineGoogle Scholar9. FarberDiamondMercerSylvesterWolff SLKRDRFJA: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (Aminopterin), New England J. Med. 238: 787, 1948. CrossrefMedlineGoogle Scholar10. PearsonElielTalbot OHLPTR: The use of ACTH and cortisone in neoplastic diseases, Bull. New York Acad. Med. 26: 235, 1950. MedlineGoogle Scholar11. BurchenalMurphyEllisonSykesTanLeoneKarnofskyCraverDargeonRhoads JHMRRMPTCLADALFHWCP: Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases, Blood 8: 965, 1953. CrossrefMedlineGoogle Scholar12. WintrobeHuguley MMCM: Nitrogen-mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias, and other disorders, Cancer 1: 357, 1948. CrossrefMedlineGoogle Scholar13. GellhornCollins AVP: A quantitative evaluation of the contribution of nitrogen mustard to the therapeutic management of Hodgkin's disease, Ann. Int. Med. 35: 1250, 1951. LinkGoogle Scholar14. AlderZbinden AF: Zur Therapie des Lymphogranulomas (Morbus Hodgkin), Schweiz. med. Wchnschr. 83: 924, 1953. MedlineGoogle Scholar15. FriendCummins DGJF: New antiemetic drug, J. A. M. A. 153: 480, 1953. CrossrefMedlineGoogle Scholar16. Gellhorn A: A critical evaluation of the current status of clinical cancer chemotherapy, Cancer Research 13: 205, 1953. MedlineGoogle Scholar17. KollerCasarini PCA: Comparison of cytological effects induced by Xrays and nitrogen mustard, Brit. J. Cancer 6: 173, 1952. CrossrefMedlineGoogle Scholar18. RundlesBarton RWWB: Triethylene melamine in the treatment of neoplastic disease, Blood 7: 483, 1952. CrossrefMedlineGoogle Scholar19. Galton DA: Myleran in chronic myeloid leukaemia, Lancet 1: 208, 1953. CrossrefGoogle Scholar20. MeachamTillotsonHeinle GCFWRW: Liver damage after prolonged urethane therapy, Am. J. Clin. Path. 22: 22, 1952. CrossrefMedlineGoogle Scholar21. BiermanCrileDodKellyPetrakisWhiteShimkin HRDMKSKHNLLPMB: Remissions in leukemia of childhood following acute infectious disease, Cancer 6: 591, 1953. CrossrefMedlineGoogle Scholar22. Tivey H: Prognosis for survival in the leukemias of childhood; review of the literature and the proposal of a simple method of reporting survival data for these diseases, Pediatrics 10: 48, 1952. MedlineGoogle Scholar23. Farber SJ: Proceedings of second conference on folic acid antagonists in treatment of leukemia, Blood 7: 107, 1952. Google Scholar24. FessasWintrobeThompsonCartwright PMMRBGE: The treatment of acute leukemia with cortisone and corticotrophin, Arch. Int. Med. In press. Google Scholar25. RosenthalSaundersSchwartzZannosSantiagoDameshek MCRHLILEPW: The use of adrenocorticotropic hormone and cortisone in the treatment of leukemia and leukosarcoma, Blood 6: 804, 1951. CrossrefMedlineGoogle Scholar26. WintrobeCartwrightPalmerKuhnsSamuels MMGEJGWJLT: Effect of corticotrophin and cortisone on the blood in various disorders in man, Arch. Int. Med. 88: 310, 1951. CrossrefGoogle Scholar27. DameshekFreedmanSteinberg WMHL: Folic acid antagonists in the treatment of acute and subacute leukemia, Blood 5: 898, 1950. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Presented as a Morning Lecture at the Thirty-fifth Annual Session of the American College of Physicians, Chicago, Illinois, April 8, 1954.From the Department of Medicine, University of Utah College of Medicine, Salt Lake City, Utah.†Fellow of the Damon Runyon Memorial Fund for Cancer Research.‡American Cancer Society Clinical Fellow. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie LymphogranulomatoseALKYLATING AGENTSChemotherapy of Hodgkin's diseaseHodgkin's Disease — Prognosis, Treatment and Etiologic and Immunologic ConsiderationsTumors and HormonesMANGANESE-INDUCED HYPOGLYCÆMIADISCLOSURE OF CONFIDENCESTRIETHYLENE MELAMINE (T.E.M.) IN ACUTE LEUKÆMIADie Lymphogranulomatose der HautCytostaticaCytologie und Klinik der LymphogranulomatoseMiliary tuberculosis occurring in patients with malignant lymphomaA potential hazard of therapySome aspects of the lymphoma problemLXV Malignant Lymphomas of the PharynxTreatment of Chronic Granulocytic Leukemia with MyleranPrednison therapy of acute lymphatic leukemia in childrenThe palliative care of inoperable and incurable recrudescent neoplasmsMASSIVE PREDNISONE AND PREDNISOLONE THERAPY IN LEUKEMIA AND LYMPHOMAS IN THE ADULT††Advances in Chemotherapy of Cancer in ManCytotoxic Agents in Malignant DiseaseProtecting the Motorist 1 September 1954Volume 41, Issue 3Page: 447-464KeywordsChemotherapeutic agentsChemotherapyDrugsHodgkin lymphomaResearch fundingSalts ePublished: 1 December 2008 Issue Published: 1 September 1954 PDF downloadLoading ...